Terapie w programie lekowym:
Leki w katalogu chemioterapii:
Aflibercept
Bevacizumab
Capecitabine
Capecitabine (2)
Carboplatin
Cetuximab
Cisplatinum
Cyklophosphamidum
Dacarbazinum
Denosumab
Doxorubicinum
Etoposidum
Fluorouracilum
Ifosfamidum
Imatinibum
Irinotecanum
Lanreotidum
Octreotidum
Oxaliplatinum
Paclitaxel
Panitumumab
Regorafenib
Sorafenib
Sunitinib
Temozolomidum
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- colorectal cancer
- rectal cancer
- » Endoscopic THerapy Or Surgery for Early Colon Cancer (ETHOS)
- » Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer: Multicentre Randomised Controlled Trial
- » A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- » A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- » A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer